title: Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis.
abstract: Ankylosing spondylitis is a chronic and progressive inflammatory disease involving the sacroiliac joints with HLA-B27 positivity in 85% of the patients and radiologically evidence of sacroiliitis. It is associated with several extraarticular manifestations, but neurological complications are rare. Occurrence of multiple sclerosis in patients with ankylosing spondylitis has been reported in limited cases. Adalimumab, a TNF-α antagonist, offers a significant improvement in ankylosing spondylitis and is considered to be less immunogenic and more tolerable than other TNF-α blockers. A case of multiple sclerosis coexisted with HLA-B27 positive ankylosing spondylitis after treated with adalimumab was reported.
authors.affiliation: Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, Noroloji Anabilim Dalı Samatya, 34340, Istanbul, Turkey.
authors.forename: Uğur
authors.initials: U
authors.lastname: Uygunoğlu
authors.forename: Derya
authors.initials: D
authors.lastname: Uluduz
authors.forename: Koray
authors.initials: K
authors.lastname: Taşçılar
authors.forename: Sabahattin
authors.initials: S
authors.lastname: Saip
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D015796:HLA-B27 Antigen / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D012307:Risk Factors; D013167:Spondylitis, Ankylosing / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015796:HLA-B27 Antigen; D007166:Immunosuppressive Agents; D000068879:Adalimumab